However, in the phase II study of BI1291583, another DPP-1 inhibitor, patients with a primary diagnosis of asthma or COPD were also included; data from future studies will clarify the effect of these drugs on patients with bronchiectasis and concomitant asthma or COPD [36]. Here, CTSC is linked to bronchiectasis.